The Oncology Institute, Inc. is classed by the SEC under Services-Offices & Clinics of Doctors of Medicine (industry code 8011), based in Cerritos, CA. In its latest annual figures on file, for the fiscal year ended 2025-12-31, it reported revenue of $503 million and a loss of $61 million (its filed statements).
Usage businessServices-Offices & Clinics of Doctors of MedicineCerritos, CAfilings since 20208 of 9 filed, 1 estimated
Three tenses, nine metrics. Unseen metrics stay unseen; the grade never fakes a number. Proxy era: provisional values, marked. Weighed as a usage business: prior from its industry code (SEC 8011, Services-Offices & Clinics of Doctors of Medicine); the filing read can change it. All three tenses have at least two readings, so the archetype blend applies as printed.
The grade, in three tenses
Headline 4.4 out of ten, 8 of 9 metrics filed and 1 estimated: past 4.0 out of ten, present 4.1 out of ten, future 5.3 out of ten. The past asks what it actually did, the present what it is doing right now, the future what it is set up to do next.
The nine metrics
Surviving crises (past): 0.6 out of ten. 8 warning events since 2020; the latest 2026-05-22. 6th percentile among 9 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
Track record (past): 5.9 out of ten. +21.8% a year over 6 filed years; profitable in 1 of 6. 59th percentile among 8 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
Shareholder treatment (past): 5.0 out of ten. CrossAssetData estimate 5.0/10, confidence 35 of 100 (one part). 50th percentile among 9 sector filers. A CrossAssetData estimate, not a filed reading: one part, confidence 35 of 100; a filing that carries the missing parts replaces this estimate with the filed reading.
Financial health (present): 1.1 out of ten. Leverage 110%: owes 110¢ per asset dollar. 11th percentile among 9 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
Industry position (present): 5.3 out of ten. top 47% of 9 in its family; net margin -12.1%. 53rd percentile among 9 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
Leadership (present): 6.0 out of ten. top 40% of 5 in its family for leadership; chief executive since 2023. 60th percentile among 5 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-09).
Room to expand (future): 2.8 out of ten. bottom 28% of 9 in its family for room to expand. 28th percentile among 9 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
Growth drivers (future): 7.7 out of ten. top 23% of 8 in its family for growth drivers. 77th percentile among 8 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
Expectations vs reality (future): 3.6 out of ten. bottom 36% of 6 in its family for expectations against reality. 36th percentile among 6 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
The filing record
Newest annual report: Form 10-K filed 2026-03-12 for the period ended 2025-12-31 (on EDGAR). Newest quarterly report: Form 10-Q filed 2026-08-06 for the period ended 2026-06-30 (on EDGAR). Newest results release: Form 8-K filed 2026-08-06 (on EDGAR). Newest filing: Form 8-K, 2026-09-02. Filings on record since 2020. Read from EDGAR 2026-10-12.
Where the revenue comes from
Product and service lines in fiscal 2025: Health Care Specialty Pharmacy 54%, Fee for Service 30%, Capitated Revenue 16%, Clinical Research Trials and Other Revenue 1%. As tagged in its annual report (Form 10-K, filed 2026-03-12).
Who runs it
Hively, Brad (Chief Executive Officer); Virnich, Daniel (Chief Executive Officer); Barasch, Richard A (Executive Chairman); Carter, Robert Ross (Chief Financial Officer); Podnos, Yale (Chief Medical Officer); England, Kristin (Chief Administrative Officer); Langsam, Jeffrey (Chief Clinical Officer); Johnson, Karen Marie (director); Kaushal, Mohit (director); Mcgeorge, Anne (director); and 7 more. 17 officers and directors have filed their own trades in the last fifteen months, names and titles as filed with the SEC, through 2026-09-30.
Every stock is a company. We grade the company behind the stock. CrossAssetData is a company research product: no investment advice, no price targets, no price predictions; every claim carries its source, and unseen means unseen. The full file draws when the page's script runs: the essentials, the balance sheet, the estimators, the trend, and every filing of the last ten years.